-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Experts Address the Hottest Topics in AML: Considerations on FLT3, IDH1/2, TP53, Maintenance, Novel Combinations and Beyond!

Sponsor: GlycoMimetics, Inc., Rigel Pharmaceuticals, Inc., Syndax Pharmaceuticals, Inc., Jazz Pharmaceuticals, Inc., Gilead Sciences, Inc., Daiichi Sankyo, Inc., and Curis, Inc.
Program: Friday Satellite Symposia
Hematology Disease Topics & Pathways:
Research, Clinical Practice (Health Services and Quality), Diseases, Therapies, Adverse Events, Biological Processes, Minimal Residual Disease
Friday, December 8, 2023: 11:00 AM-2:00 PM
Room 6A (San Diego Convention Center)
Naval Daver, MD, The University of Texas MD Anderson Cancer Center
Daver: Bristol-Myers Squibb: Consultancy, Research Funding; Genentech: Consultancy, Research Funding; Trillium: Consultancy, Research Funding; Celgene: Consultancy; Jazz: Consultancy; Kite, a Gilead company: Consultancy, Research Funding; Novimmune: Research Funding; Astellas: Consultancy, Research Funding; AbbVie: Consultancy, Research Funding; Glycomimetics: Research Funding; Daiichi Sankyo: Consultancy, Research Funding; Servier: Consultancy, Research Funding; Pfizer: Consultancy, Research Funding; Syndax: Consultancy; Amgen: Consultancy, Research Funding; Kronos Bio: Research Funding; Agios: Consultancy; Gilead: Consultancy, Research Funding; Trovagene: Research Funding; Novartis: Consultancy; AROG: Consultancy; FATE: Research Funding; ImmunoGen: Consultancy, Research Funding; Shattuck Labs: Consultancy; Hanmi: Research Funding.
Eytan M. Stein, Memorial Sloan Kettering Cancer Center , Courtney D. DiNardo, MD, MSc, The University of Texas MD Anderson Cancer Center , Gail J. Roboz, MD, Weill Cornell Medicine and The New York Presbyterian Hospital and Amir T. Fathi, MD, Massachusetts General Hospital
Stein: Gilead: Consultancy; OnCusp: Consultancy; Genesis: Consultancy; Syros: Consultancy; Syndax: Consultancy; Foghorn: Consultancy; Calithera: Consultancy; Servier: Consultancy; Neoleukin: Consultancy; Menarini: Consultancy; Jazz: Consultancy; Daiichi: Consultancy; Agios: Consultancy; CTI Biopharma: Consultancy; Abbvie: Consultancy; Aptose: Consultancy; Eisai: Research Funding; Janssen: Consultancy; Bristol Myers Squib: Consultancy, Research Funding; Genentech: Consultancy; PinotBio: Consultancy; Novartis: Consultancy; Astellas: Consultancy; Ono Pharma: Consultancy; Blueprint: Consultancy. DiNardo: BMS: Honoraria; ImmuniOnc: Honoraria; Astellas: Honoraria; Notable Labs: Honoraria; AbbVie/Genentech: Honoraria; Servier: Honoraria; Fogham: Honoraria; Novartis: Honoraria; Takeda: Honoraria; Schrödinger: Consultancy. Roboz: AZ: Consultancy; Blueprint: Consultancy; GSK: Consultancy; Janssen: Consultancy, Research Funding; Pfizer: Consultancy; Bluebird bio: Consultancy; MEI: Consultancy; BMS: Consultancy; Takeda: Consultancy; Novartis: Consultancy; Syndax: Consultancy; Jazz: Consultancy; Mesoblast: Consultancy; AbbVie: Consultancy; Astellas: Consultancy; Amgen: Consultancy; Agios: Consultancy; Actinium: Consultancy; Jasper: Consultancy. Fathi: AbbVie: Consultancy, Research Funding; Agios: Consultancy; Amgen: Consultancy; Orum: Consultancy; Menarini: Consultancy; Gilead: Consultancy; Takeda: Consultancy; Rigel: Consultancy; Servier: Consultancy, Research Funding; Remix: Consultancy; PureTech: Consultancy; Pfizer: Consultancy; Novartis: Consultancy; Mablytics: Consultancy; Ipsen: Consultancy; Kite: Consultancy; Immunogen: Consultancy; Genentech: Consultancy; Daiichi Sankyo: Consultancy; Forma: Consultancy; Enclear: Consultancy; Celgene: Consultancy, Research Funding; Autolus: Consultancy; Bristol-Myers Squibb: Consultancy, Research Funding; Astellas: Consultancy.
Access Program Details

The live activity will feature a series of didactic presentations coupled with case-based panel discussions and question-and-answer sessions from the audience. Using a blended instructional model of didactic presentations and interactive panel discussions is intended is to improve medical practices and patient care through evidence-based presentations, discussion, and authoritative peer-exchange on important clinical issues. The satellite program will bring together 5 clinical experts to highlight novel agents in the management of AML, including the latest clinical data and application of targeted therapies, combination, maintenance therapy, and beyond.